drugset / Trial / NCT00824161
Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clinical benefit, overall survival, and the safety profile of TAS-109
Timeline
- Start
- 2009-01
- Primary completion
- 2009-11
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAS-109 | Small molecule | 2 mg/m2 | Intravenous |